GENFLOW BIOSCIENCES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.175 GBX | +1.16% |
|
+17.57% | +52.63% |
| 08/05 | Home REIT cuts borrowings, Genflow shares restored | AN |
| 08/05 | Genflow Biosciences Resumes London Trading | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 7.02 | 4.168 |
| Enterprise Value (EV) 1 | 4.664 | 3.484 |
| P/E ratio | -5.26 x | -2.56 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | -34,94,070 x | -21,40,632 x |
| EV / FCF | -49,52,642 x | -33,18,341 x |
| FCF Yield | -0% | -0% |
| Price to Book | 2.97 x | 5.74 x |
| Nbr of stocks (in thousands) | 2,92,507 | 2,92,507 |
| Reference price 2 | 0.0240 | 0.0142 |
| Announcement Date | 08/06/23 | 07/05/24 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net sales | - | - | - |
| EBITDA | - | -1.335 | -1.628 |
| EBIT 1 | -0.6499 | -1.335 | -1.629 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) 1 | -0.651 | -1.335 | -1.629 |
| Net income 1 | -0.651 | -1.335 | -1.629 |
| Net margin | - | - | - |
| EPS 2 | -0.8177 | -0.004565 | -0.005570 |
| Free Cash Flow | - | -0.9417 | -1.05 |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 07/01/22 | 08/06/23 | 07/05/24 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net Debt 1 | - | - | - |
| Net Cash position 1 | 0.25 | 2.36 | 0.68 |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow | - | -0.94 | -1.05 |
| ROE (net income / shareholders' equity) | - | -110% | -105% |
| ROA (Net income/ Total Assets) | - | -57.7% | -55.2% |
| Assets 1 | - | 2.316 | 2.951 |
| Book Value Per Share 2 | 0.0300 | 0.0100 | 0 |
| Cash Flow per Share 2 | 0.0400 | 0.0100 | 0 |
| Capex | - | 0 | 0 |
| Capex / Sales | - | - | - |
| Announcement Date | 07/01/22 | 08/06/23 | 07/05/24 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +52.63% | 95.27L | |
| +8.89% | 11TCr | |
| +11.47% | 10TCr | |
| -12.69% | 2.24TCr | |
| -1.05% | 2.23TCr | |
| -5.29% | 1.91TCr | |
| -38.29% | 1.8TCr | |
| -3.15% | 1.79TCr | |
| +8.12% | 1.43TCr | |
| +34.69% | 1.25TCr |
- Stock Market
- Equities
- GENF Stock
- Financials Genflow Biosciences plc
